Gynecologic oncology Clinical Trials

Recruiting gynecologic oncology studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat gynecologic oncology. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting gynecologic oncology studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting gynecologic oncology trials

Within

Development of Systems and Education for Cervical Cancer Prevention (DOSE-CC)

for Cervical Cancer Screening

Sponsor: Boston Medical Center

Sex: Female·Age: 21 - 65

Code: NCT07226037

SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer

for Endometrial Cancer

Sponsor: Hospital Universitari de Bellvitge

Sex: Female·Age: 18+

Code: NCT07462663·Phase 4

Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab

for Ovarian Cancer

1 site in Charleston

Sponsor: Medical University of South Carolina

Sex: Female·Age: 18 - 80

Code: NCT07720180·Phase 2

Breast and Cervical Cancer Stigma in Rwanda

for Breast Cancer

Sponsor: Dana-Farber Cancer Institute

Sex: Female·Age: 18+

Code: NCT07663006

Signatera Assessment in Early-Stage Endometrial Cancer

for Endometrial Cancer

12 sites incl. Birmingham

Sponsor: Natera, Inc.

Sex: Female·Age: 18+

Code: NCT07339384

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

for Endometrial Neoplasms

4 sites incl. Bellevue

Sponsor: Pfizer

Sex: Female·Age: 18+

Code: NCT07578649·Phase 3

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

for Fallopian Tube Carcinoma

1 site in Seattle

Sponsor: University of Washington

Sex: Female·Age: 18+

Code: NCT07495124·Phase 2

OCRA Distress & Unmet Needs

for Gynecologic Cancer

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07591623

An International Field Study of the Reliability and Validity of a Disease-Specific Questionnaire Module (the QLQ-OV28) in Assessing the Quality of Life of Patients With Ovarian Cancer - Phase III

for Ovarian Cancer

Sponsor: Helios University Hospital Wuppertal

Sex: Female·Age: 18+

Code: NCT07465133

Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression

for Ovarian Cancer

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Sex: Female·Age: 18 - 70

Code: NCT07168083

Predictors of Cognitive Decline and Delirium in Older Women With Ovarian Cancer

for Ovarian Cancer

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Sex: Female·Age: 70+

Code: NCT07716800

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

for Endometrial Cancer

1 site in Chapel Hill

Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: Female·Age: 18+

Code: NCT07078838·Phase 2

PITCH - Impacting Hereditary Cancer Testing

for Ovarian Cancer

1 site in Lexington

Sponsor: Rachel Miller

Sex: Female·Age: 18+

Code: NCT07090109

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

for Ovarian Cancer

1 site in Pittsburgh

Sponsor: Kalinski, Pawel, MD, PhD

Sex: Female·Age: 18+

Code: NCT07634094·Phase 2

Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

for Ovarian Cancer

Sponsor: ARCAGY/ GINECO GROUP

Sex: Female·Age: 18+

Code: NCT07637851·Phase 1, Phase 2

A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

for Ovarian Cancer

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

Sex: All·Age: 18+

Code: NCT07714668·Phase 2

Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies

for Gynecologic Cancer

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Sex: Female·Age: 18 - 99

Code: NCT07702721

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

for Advanced Cervical Carcinoma

1 site in St Louis

Sponsor: Washington University School of Medicine

Sex: All·Age: 18+

Code: NCT05521997·Phase 2

Massage, Oncology, Pain, Anxiety, Feasibility

for Gynecologic Cancer

1 site in Lexington

Sponsor: Jill Cole

Sex: Female·Age: 18 - 85

Code: NCT07502157

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

for Epithelial Ovarian Cancer

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Sex: All·Age: 18 - 75

Code: NCT07545460·Phase 3

Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

for Platinum-Sensitive Ovarian Cancer

2 sites incl. Danbury

Sponsor: Genmab

Sex: Female·Age: 18+

Code: NCT07564141·Phase 3

Apply to this trial

Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer

for Gynecologic Cancer

1 site in Lexington

Sponsor: Denise Fabian

Sex: Female·Age: 18+

Code: NCT07631572

Apply to this trial

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

for Ovarian Cancer

Sponsor: Epitopea Ltd

Sex: Female·Age: 18+

Code: NCT07665515·Phase 1

Apply to this trial

A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery

for Ovarian Cancer

Sponsor: West China Hospital

Sex: Female·Age: 18 - 75

Code: NCT07676890·Phase 1

DISARM Clinical Study B: Evaluation of Innovative Ovarian Cancer Biomarker Assays

for Ovarian Cancer

Sponsor: National and Kapodistrian University of Athens

Sex: Female·Age: 35+·Accepts healthy volunteers

Code: NCT07693894

Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers

for HIV (Human Immunodeficiency Virus)

Sponsor: Shenzhen Third People's Hospital

Sex: All·Age: 18+

Code: NCT07696169

Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia

for Endometrial Neoplasms

Sponsor: Peking University People's Hospital

Sex: Female·Age: Up to 46

Code: NCT07714070·Phase 2

A Real-World Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α

for Ovarian Cancer

Sponsor: NING LI-GYN

Sex: Female·Age: 18+

Code: NCT07690332

Evaluation of XYA02 in Patients With Advanced Solid Tumors

for MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors

Sponsor: XYone Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT07670312·Phase 1, Phase 2

Low-Residue Diet Versus Rectal Enema Before Laparoscopic Surgery for Endometrial Cancer

for Endometrial Cancer

Sponsor: Mahmut Yassa

Sex: Female·Age: 18 - 90

Code: NCT07702799

Apply to this trial

SL-28 for Advanced Solid Tumours

for Head & Neck Cancer

Sponsor: Second Life Therapeutics

Sex: All·Age: 18+

Code: NCT07341737·Phase 1, Phase 2

Apply to this trial

Study of EV for Recurrent Endometrial Carcinoma

for Endometrial Cancer

1 site in Milwaukee

Sponsor: William Bradley

Sex: Female·Age: 18+

Code: NCT07139977·Phase 2

Apply to this trial

Application of Cardiophrenic Lymphadenectomy in Advanced Ovarian Cancer: A Single-Center Prospective Exploratory Study

for Ovarian Cancer

Sponsor: manxiaxia

Sex: Female·Age: 18 - 70

Code: NCT07572409

Apply to this trial

Prospective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection

for Ovarian Neoplasms

Sponsor: Tongji Hospital

Sex: Female·Age: All ages

Code: NCT07593833

Effect of Web-Based Education on Attitudes and Beliefs About HPV Testing

for Cervical Cancer

Sponsor: Sakarya University

Sex: Female·Age: 18 - 60·Accepts healthy volunteers

Code: NCT07620795

COQ10 and Vitamin E for Off-Target Radiation Toxicity

for Prostate Cancer

1 site in Omaha

Sponsor: University of Nebraska

Sex: All·Age: 19+

Code: NCT07668284·Phase 1, Phase 2

Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy

for Ovarian Neoplasms

Sponsor: Asan Medical Center

Sex: Female·Age: 19+

Code: NCT07670962

SENTInel Node Mapping Versus Comprehensive Lymphadenectomy in p53-Mutated Endometrial Cancer: A Non-Inferiority Randomized Trial

for Lymphadenectomy

Sponsor: University Hospital, Strasbourg, France

Sex: Female·Age: 18+

Code: NCT06900582

My Self-Sampling for HPV Awareness, Results, and Empowerment

for Cervical Cancer

Sponsor: Daisy Le

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07296159

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

for PIK3CA Mutations

4 sites incl. Scottsdale

Sponsor: Cogent Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT07383506·Phase 1

Apply to this trial

C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States

for Human Immunodeficiency Virus (HIV)

2 sites incl. Atlanta

Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All·Age: 25 - 49·Accepts healthy volunteers

Code: NCT07520188

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

for Breast Cancer

5 sites incl. Los Angeles

Sponsor: Regor Pharmaceuticals Inc.

Sex: All·Age: 18+

Code: NCT07524322·Phase 1

Apply to this trial

Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

for Ovarian Cancer

Sponsor: Chong Kun Dang Pharmaceutical

Sex: Female·Age: 19 - 75

Code: NCT07532148·Phase 1

PRIORITY Study in Cervical Cancer

for Cervical Cancer

Sponsor: Pontificia Universidad Catolica de Chile

Sex: Female·Age: 30 - 65·Accepts healthy volunteers

Code: NCT07593066

Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

for Ovarian Cancer

9 sites incl. Detroit

Sponsor: Xencor, Inc.

Sex: Female·Age: 18+

Code: NCT07593092·Phase 1

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

for Solid Tumor

Sponsor: Huahui Health

Sex: All·Age: 18 - 75

Code: NCT07623369·Phase 1

Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

for Cervical Cancer

Sponsor: Hunan Cancer Hospital

Sex: Female·Age: 18 - 75

Code: NCT07627620·Phase 2

68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors

for Prostate Cancer

Sponsor: Peking University Cancer Hospital & Institute

Sex: All·Age: 18 - 75

Code: NCT07639801

Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer

for Ovarian Cancer

Sponsor: Shandong University

Sex: Female·Age: 18+

Code: NCT07647653·Phase 2

NK521 in the Treatment of Advanced Solid Tumors

for Hepatocellular Carcinoma (HCC)

Sponsor: Base Therapeutics (Shanghai) Co., Ltd.

Sex: All·Age: 18 - 65

Code: NCT07657416·EARLY_Phase 1

A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

for Endometrial Cancer Recurrent

Sponsor: Outpace Bio, Inc.

Sex: Female·Age: 18+

Code: NCT07664735·Phase 1

Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer

for Cervical Cancer

Sponsor: Zhejiang Cancer Hospital

Sex: Female·Age: 18+

Code: NCT07673211

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

for Ovarian Cancer

1 site in Chicago

Sponsor: University of Chicago

Sex: All·Age: 18+

Code: NCT07389239·Phase 1, Phase 2

QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer

for Cervical Cancer

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Sex: Female·Age: 18 - 65

Code: NCT07617818·Phase 2

Prehabilitation in High-risk Oncologic Surgery

for Pancreatic Cancer

Sponsor: Fox Chase Cancer Center

Sex: All·Age: 18+

Code: NCT07638410

Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy

for Gastric Cancer

Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07676461

Apply to this trial

Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer

for Endometrial Cancer

1 site in New Brunswick

Sponsor: Rutgers, The State University of New Jersey

Sex: Female·Age: 18 - 90

Code: NCT07643012

Apply to this trial

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

for Ovarian Cancer

3 sites incl. Fort Lauderdale

Sponsor: University of Miami

Sex: Female·Age: 18+

Code: NCT06412120·Phase 4

Apply to this trial

Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial

for Cervical Cancer

Sponsor: Obstetrics & Gynecology Hospital of Fudan University

Sex: Female·Age: 18 - 75

Code: NCT07649174·Phase 2

Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II）

for Ovarian Cancer

Sponsor: Obstetrics & Gynecology Hospital of Fudan University

Sex: Female·Age: 18 - 75

Code: NCT07673835·Phase 2

Gynecologic oncology clinical trials — common questions

Are gynecologic oncology clinical trials free to join?

Yes. Participating in a gynecologic oncology clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Who can join a gynecologic oncology clinical trial?

Each gynecologic oncology study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

How do I find a gynecologic oncology trial near me?

Use the location controls above. We'll show recruiting gynecologic oncology trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

How many gynecologic oncology trials are recruiting right now?

We're currently tracking roughly 471 recruiting gynecologic oncology trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Looking for a specific location? Browse trials by city and state.

Gynecologic oncology trials by city

Birmingham, AL Boston, MA Los Angeles, CA Chicago, IL Duarte, CA San Francisco, CA Little Rock, AR Aurora, CO Denver, CO La Jolla, CA Orlando, FL Salt Lake City, UT

Conditions in this area

Ovarian cancer Endometrial cancer Cervical cancer Uterine cancer Fallopian tube cancer Gynecologic cancer